Clinical trials
Vasculitis clinical trials
Below are recruiting vasculitis clinical trials, each written for real people, not researchers. We’re tracking 99 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03004326Recruiting
Biopsy study to test skin inflammation gene signals
This study uses a skin biopsy to look at “gene signals” (transcriptomics) in patients with active vasculitis that shows up on the skin. It may help researchers understand what is happening in your disease and how different types of vasculitis differ.
Los Angeles, CaliforniaAges 5 years+ - NCT02593565Recruiting
Pregnancy blood-vessel disease registry study
This is a pregnancy registry that collects information from people with certain blood-vessel inflammatory diseases during pregnancy. It helps researchers better understand these conditions in pregnancy and may guide future care.
Tampa, FloridaAges 18–50 - NCT05734404Recruiting
Long-term study of brain vessel inflammation
This study follows adults diagnosed with inflammation of blood vessels in the brain (CNS vasculitis). It aims to better understand the condition over time and could help improve how it’s diagnosed and managed.
Rochester, MinnesotaAges 18 years+ - NCT02939573RecruitingPhase 2
Study of medicines for skin-only vasculitis flares
This Phase 2 trial tests different medicines to calm active skin vasculitis and prevent flare-ups. It’s for people whose vasculitis mainly affects the skin, not major organs like kidneys or the brain.
Kansas City, KansasAges 18 years+ - NCT07268521RecruitingPhase 2
Obinutuzumab for cryoglobulinemia vasculitis after rituximab failure
This trial tests if the drug obinutuzumab can help people with a blood vessel inflammation called cryoglobulinemia vasculitis when rituximab no longer works or causes side effects. It is a single-arm study, meaning everyone gets the new drug.
BloisAges 18 years+ - NCT07258524Recruiting
Vasculitis PET scan trial for heart disease risk
This trial uses a special PET scan to look at inflammation in blood vessels and check heart disease risk in people with active ANCA-associated vasculitis (AAV). It may help doctors understand how to better manage heart health during treatment.
EdinburghAges 18 years+ - NCT07168161RecruitingPhase 3
BDB-001 for ANCA vasculitis (GPA/MPA) trial
This trial tests a new drug called BDB-001 for people with a type of blood vessel inflammation (ANCA vasculitis, specifically GPA or MPA). It aims to see if adding BDB-001 to standard treatment can help control the disease better.
Beijing, Beijing MunicipalityAges 18–75 - NCT07160608RecruitingPhase 2
Study of Tarperprumig for ANCA-associated vasculitis
This trial tests a new drug (tarperprumig) for people with active ANCA-associated vasculitis (GPA or MPA). The goal is to see if it is safe and effective for treating the disease, especially when standard treatments like rituximab or cyclophosphamide are being considered.
Ciudad de Buenos AiresAges 18–80 - NCT07151521Recruiting
FAPI PET/CT in ANCA vasculitis with lung disease
This study uses a special PET/CT scan (called FAPI) to look at inflammation in people with ANCA-associated vasculitis and interstitial lung disease. It may help doctors see how active the disease is and guide treatment.
ShanghaiAges 18 years+ - NCT07586137Recruiting
Understanding Systemic Vasculitis: A Long-Term Health Study
This study follows people with systemic vasculitis (inflammation of blood vessels throughout the body) to better understand how the disease progresses and what outcomes to expect. Researchers will collect health information over time to improve treatment and care for vasculitis patients.
Pavia, PaviaAges 18 years+ - NCT07024563RecruitingPhase 3
Testing ravulizumab for kids with IgA nephropathy
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Palo Alto, CaliforniaAges 2–18 - NCT07010250Recruiting
Kidney Energy Use and Scarring in ANCA Vasculitis
This study looks at how kidney cells use energy and how that leads to scarring in people with ANCA vasculitis. It compares findings with people who have other kidney diseases to better understand and possibly treat kidney damage.
ParisAges 18–90 - NCT06887062RecruitingPhase 2
Testing dapagliflozin and bosentan for large vessel vasculitis
This trial tests two drugs, dapagliflozin and bosentan, to see if they help people with large vessel vasculitis who have been in remission for at least 6 months. The goal is to prevent flares and improve blood vessel health.
EdinburghAges 18 years+ - NCT06824714Recruiting
Predicting blood vessel damage in large vessel vasculitis
This study uses PET and MRA scans to predict damage to large blood vessels in people who have or may have large vessel vasculitis (LVV). It aims to find at-risk patients early so they can get better care. You'll need to be willing to have both scans and come back for long-term check-ups.
Nanjing, JiangsuAges 18 years+ - NCT06794827Recruiting
Early access avacopan for ANCA vasculitis
This study looks at how well the drug avacopan works for people with a rare blood vessel disease called ANCA-associated vasculitis. It aims to help patients who are starting this treatment by tracking real-world results.
LeidenAges 16 years+ - NCT06642870Recruiting
Self-management programme for rare rheumatic conditions
This trial is developing a self-management programme for people with rare rheumatic conditions like lupus, vasculitis, myositis, or Sjogren syndrome. It aims to help participants better manage their condition and improve their quality of life.
BristolAges 18 years+ - NCT06611696RecruitingPhase 4
Avacopan vs lower-dose steroids for new vasculitis
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
Toyoake, Aichi-kenAges 18 years+ - NCT06277427Recruiting
CAR-T cell therapy for refractory vasculitis and lupus nephritis
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
Wuhan, HubeiAges 18–70 - NCT07664228Recruiting
Predicting stomach pain in children with IgA vasculitis
This study looks at a blood test done when a child is first diagnosed with IgA vasculitis (also called Henoch-Schönlein purpura) to see if it can predict stomach or intestine problems. It involves one extra blood draw at diagnosis and a follow-up visit a few weeks later.
Bursa, BursaAges 2–18 - NCT05364892Recruiting
Biobank study for ANCA-associated vasculitis patients
This study collects and stores health information and possibly samples from people diagnosed with ANCA-associated vasculitis to help researchers learn more about the disease. It may help future studies, but it is mainly focused on collection rather than testing a new treatment.
Brest, BrestAges 18–99 - NCT05946564RecruitingPhase 3
Pioglitazone to protect kidney function in ANCA vasculitis
This Phase 3 trial tests whether pioglitazone can help protect kidney function in people with newly diagnosed or relapsing ANCA-associated vasculitis that is actively affecting the kidneys. It aims to improve “renal tolerance,” meaning your kidneys may be better able to tolerate the disease and treatment.
AmiensAges 18–80 - NCT06072482RecruitingPhase 4
Avacopan for ANCA-associated vasculitis
This trial tests a medication called avacopan for people with ANCA-associated vasculitis, a condition where the immune system attacks blood vessels. Avacopan is taken with standard treatments to help control the disease and may reduce the need for steroids.
Anchorage, AlaskaAges 18–100 - NCT05965284RecruitingPhase 4
Telitacicept to help keep ANCA vasculitis in remission
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
Beijing, Beijing MunicipalityAges 18–65 - NCT05962840RecruitingPhase 4
Rituximab plus telitacicept for ANCA vasculitis
This Phase 4 trial studies whether rituximab combined with telitacicept works better and is safe for people with severe active ANCA-associated vasculitis (including certain subtypes like GPA or MPA). If you meet specific blood test and disease activity criteria, you may be considered to help lower inflammation and prevent flare-ups.
BeijingAges 18–65
Hear when a new Vasculitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Vasculitis trials by city
Studies with a site in or near these metro areas.
Vasculitis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for vasculitis?
- Yes. Clin2 currently lists 99 recruiting vasculitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a vasculitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a vasculitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.